Gov. good point, these pharma that have 1 or 2 drugs phase 1 with 1-5 billion market caps may have given away too many rights to big pharma too early for short term gain. Leo's strategy of developing them first in the long-run should be best for shareholder equity. Powder-keg situation!
Still frustrating though. Clovis etc often have drugs for rare cancers no big revenue projections but a faster path to approval but Cellceutix have this as well with there big 3 and it takes a massive tornado of data releases and news catalysts to get us to a 300m market cap.
Market Data 
Markets 
AI
